Consolidated Statements of Stockholders’ (Deficit) Equity - USD ($) $ in Thousands	Total	At Market Equity Offering Program	Common Stock	Common Stock At Market Equity Offering Program	Additional Paid-in Capital	Additional Paid-in Capital At Market Equity Offering Program	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at beginning of period (in shares) at Dec. 31, 2021			73,709,056
Balance at beginning of period at Dec. 31, 2021	$ 121,741		$ 7		$ 572,213		$ 0	$ (450,479)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				30,497,875
Issuance of common stock from at-the-market transactions, net of issuance costs		$ 150,762	$ 4			$ 150,758
Exercise of stock options (in shares)			414,914
Exercise of stock options	1,331				1,331
Exercise of common stock warrant (in shares)			16,654
Vesting of restricted stock units (in shares)			235,591
Sales of common stock pursuant to ESPP (in shares)			270,774
Sales of common stock pursuant to ESPP	1,065				1,065
Stock-based compensation expense	21,522				21,522
Other comprehensive (loss) income	(152)						(152)
Net loss	(204,212)							(204,212)
Balance at end of period (in shares) at Dec. 31, 2022			105,144,864
Balance at end of period at Dec. 31, 2022	92,057		$ 11		746,889		(152)	(654,691)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				14,464,531
Issuance of common stock from at-the-market transactions, net of issuance costs		93,670		$ 1		93,669
Exercise of stock options (in shares)			102,596
Exercise of stock options	427				427
Vesting of restricted stock units (in shares)			618,246
Sales of common stock pursuant to ESPP (in shares)			381,508
Sales of common stock pursuant to ESPP	1,121				1,121
Stock-based compensation expense	21,136				21,136
Other comprehensive (loss) income	163						163
Net loss	(171,670)							(171,670)
Balance at end of period (in shares) at Dec. 31, 2023			120,711,745
Balance at end of period at Dec. 31, 2023	36,904		$ 12		863,242		11	(826,361)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock from at-the-market transactions, net of issuance costs (in shares)				1,041,201
Issuance of common stock from at-the-market transactions, net of issuance costs		$ 5,780				$ 5,780
Retirement of common stock in exchange for pre-funded warrants (in shares)			(8,036,688)
Retirement of common stock in exchange for pre-funded warrants	(13,984)				(13,984)
Issuance of pre-funded warrants in exchange for retirement of common stock	$ 13,984				13,984
Exercise of stock options (in shares)	14,223		14,223
Exercise of stock options	$ 56				56
Vesting of restricted stock units (in shares)			1,634,811
Sales of common stock pursuant to ESPP (in shares)			284,636
Sales of common stock pursuant to ESPP	486				486
Stock-based compensation expense	16,458				16,458
Other comprehensive (loss) income	(1)						(1)
Net loss	(69,192)							(69,192)
Balance at end of period (in shares) at Dec. 31, 2024			115,649,928
Balance at end of period at Dec. 31, 2024	$ (9,509)		$ 12		$ 886,022		$ 10	$ (895,553)